Biomednewsbreaks - Nanoviricides (NYSE American: NNVC) CEO Featured In Latest Episode Of PODD Podcast

(MENAFN- Investor Brand Network) NanoViricides (NYSE American: NNVC) , a clinical-stage global leader in broad-spectrum antiviral nanomedicines, is in the spotlight in the most recent episode of the PODD podcast. The company announced that president and executive chair Anil R. Diwan, PhD, was interviewed during the Oct. 11 episode of the program, which was released on PharmaTalkRadio. During the interview, Diwan discussed the company's proprietary nanoviricides technology platform as well as
its potentially revolutionary broad-spectrum antiviral clinical drug candidate, NV-387. According to the announcement, based on animal model studies, NV-387 exhibits potential to completely revolutionize the treatment of viral infections, much like penicillin changed the treatment of bacterial infections decades ago.

To listen to the episode, visit

To view the full press release, visit

About NanoViricides Inc.

NanoViricides is a clinical-stage company that is creating special-purpose nanomaterials for antiviral therapy. The company's novel nanoviricide(TM) class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma Inc. The company has a Memorandum of Understanding (“MOU”) with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MOU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. To learn more about the company, visit .

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN15102024000224011066ID1108781572